<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANP</journal-id>
<journal-id journal-id-type="hwp">spanp</journal-id>
<journal-title>Australian &amp; New Zealand Journal of Psychiatry</journal-title>
<issn pub-type="ppub">0004-8674</issn>
<issn pub-type="epub">1440-1614</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0004867411433974</article-id>
<article-id pub-id-type="publisher-id">10.1177_0004867411433974</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Correspondence</subject>
<subj-group subj-group-type="heading">
<subject>Letters</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Products containing synthetic cannabinoids and psychosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Brakoulias</surname><given-names>Vlasios</given-names></name>
</contrib>
<aff id="aff1-0004867411433974">Discipline of Psychiatry, The University of Sydney and Nepean Hospital, Penrith, Australia</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0004867411433974">Vlasios Brakoulias, Discipline of Psychiatry, The University of Sydney and Nepean Hospital, Penrith, NSW 2751, Australia. Email: <email>vbrakoulias@bigpond.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>46</volume>
<issue>3</issue>
<fpage>281</fpage>
<lpage>282</lpage>
<permissions>
<copyright-statement>© The Royal Australian and New Zealand College of Psychiatrists 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The Royal Australian and New Zealand College of Psychiatrists</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>To the Editor</p>
<p>In June 2011, products containing synthetic cannabinoids were banned in Western Australia (<xref ref-type="bibr" rid="bibr7-0004867411433974">Sydney Morning Herald, 2011</xref>; <xref ref-type="bibr" rid="bibr1-0004867411433974">Daily Telegraph, 2011</xref>). Elsewhere, they are sold in tobacco shops and are widely available (<xref ref-type="bibr" rid="bibr7-0004867411433974">Sydney Morning Herald, 2011</xref>; <xref ref-type="bibr" rid="bibr1-0004867411433974">Daily Telegraph, 2011</xref>). These products are most commonly known as ‘kronic’ or ‘kronic black’ in Western Sydney, but are also known as ‘spice’, ‘K2’, ‘purple haze’, ‘kaos’, ‘dream’, and ‘voodoo’. Often these products are sold as mixtures of herbs and they are of particular relevance to Australian mining communities where they are not detected by urine drug testing (<xref ref-type="bibr" rid="bibr7-0004867411433974">Sydney Morning Herald, 2011</xref>). There have been several case reports published internationally associating these products with psychosis (<xref ref-type="bibr" rid="bibr4-0004867411433974">Muller et al., 2010</xref>; <xref ref-type="bibr" rid="bibr3-0004867411433974">Johnson et al., 2011</xref>; <xref ref-type="bibr" rid="bibr5-0004867411433974">Schneir et al., 2011</xref>; <xref ref-type="bibr" rid="bibr6-0004867411433974">Simmons et al., 2011</xref>).</p>
<p>Although these products are reported to have been available in Australia for the last 2 years (<xref ref-type="bibr" rid="bibr1-0004867411433974">Daily Telegraph, 2011</xref>), only in recent months has the problem of synthetic cannabis products and psychosis been recognized in patients presenting to Nepean hospital, Sydney. In these cases, psychosis has been associated with more agitation than would be expected from cannabis alone. This has been reported in case reports (<xref ref-type="bibr" rid="bibr4-0004867411433974">Muller et al., 2010</xref>; <xref ref-type="bibr" rid="bibr5-0004867411433974">Schneir et al., 2011</xref>; <xref ref-type="bibr" rid="bibr6-0004867411433974">Simmons et al., 2011</xref>) and has been hypothesized to be related to differences in its chemical structure and in particular the absence of cannabidiol (CBD) which in itself is presumed to have antipsychotic potency (<xref ref-type="bibr" rid="bibr2-0004867411433974">Every-Palmer, 2011</xref>).</p>
<p>Synthetic cannabinoid products are associated with psychosis, more prominent agitation, and are not detected by routine drug testing. Clinicians should consider screening for synthetic cannabinoid use when interviewing patients presenting with psychosis or agitation.</p>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-0004867411433974">
<citation citation-type="web">
<collab>Daily Telegraph</collab> (<year>2011</year>) ‘<article-title>Fake pot known as kronic is a very chronic concern</article-title>’. <day>20</day> <month>May</month> <year>2011</year>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.news.com.au/national/fake-pot-known-as-kronic-is-a-very-chronic-concern/story-e6frfkvr-1226059326932">http://www.news.com.au/national/fake-pot-known-as-kronic-is-a-very-chronic-concern/story-e6frfkvr-1226059326932</ext-link></comment> (<access-date>accessed September 2011</access-date>).</citation>
</ref>
<ref id="bibr2-0004867411433974">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Every-Palmer</surname><given-names>S</given-names></name>
</person-group> (<year>2011</year>) <article-title>Synthetic cannabinoid JWH-018 and psychosis: an exploratory study</article-title>. <source>Drug and Alcohol Dependence</source> <volume>117</volume>: <fpage>152</fpage>–<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr3-0004867411433974">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>LA</given-names></name>
<name><surname>Johnson</surname><given-names>RL</given-names></name>
<name><surname>Alfonzo</surname><given-names>C</given-names></name>
</person-group> (<year>2011</year>) <article-title>Spice: a legal marijuana equivalent</article-title>. <source>Military Medicine</source> <volume>176</volume>: <fpage>718</fpage>–<lpage>720</lpage>.</citation>
</ref>
<ref id="bibr4-0004867411433974">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muller</surname><given-names>H</given-names></name>
<name><surname>Sperling</surname><given-names>W</given-names></name>
<name><surname>Kohrmann</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes</article-title>. <source>Schizophrenia Research</source> <volume>118</volume>: <fpage>309</fpage>–<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr5-0004867411433974">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schneir</surname><given-names>AB</given-names></name>
<name><surname>Cullen</surname><given-names>J</given-names></name>
<name><surname>Ly</surname><given-names>BT</given-names></name>
</person-group> (<year>2011</year>) <article-title>‘Spice’ girls: synthetic cannabinoid intoxication</article-title>. <source>Journal of Emergency Medicine</source> <volume>40</volume>: <fpage>296</fpage>–<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr6-0004867411433974">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simmons</surname><given-names>J</given-names></name>
<name><surname>Cookman</surname><given-names>L</given-names></name>
<name><surname>Kang</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Three cases of ‘spice’ exposure</article-title>. <source>Clinical Toxicology</source> <volume>49</volume>: <fpage>431</fpage>–<lpage>433</lpage>.</citation>
</ref>
<ref id="bibr7-0004867411433974">
<citation citation-type="web">
<collab>Sydney Morning Herald</collab> (<year>2011</year>) ‘<article-title>Kronic a bad trip for the law</article-title>’ <day>15</day> <month>June</month> <year>2011</year>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.smh.com.au/lifestyle/diet-and-fitness/kronic-a-bad-trip-for-the-law-20110615-1g3de.html">http://www.smh.com.au/lifestyle/diet-and-fitness/kronic-a-bad-trip-for-the-law-20110615-1g3de.html</ext-link></comment> (<access-date>accessed September 2011</access-date>).</citation>
</ref>
</ref-list>
</back>
</article>